Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 5, 2009, Pages 482-496

  Zhao, Wei Qin ^a   Townsend, Matthew ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt; Alzheimer's disease; Amyloid oligomer; Calcium; Diabetes; Excitotoxicity; Glucose metabolism; GSK3; IAPP; Insulin receptor substrate; Memory; Neuronal insulin resistance; Serine and threonine phosphorylation; Synaptic plasticity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GLUCOSE; INSULIN; INSULIN RECEPTOR; OLIGOMER; THREONINE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMYLOIDOGENESIS; BRAIN FUNCTION; CALCIUM SIGNALING; COGNITION; DIABETES MELLITUS; DISEASE COURSE; DOWN REGULATION; ENERGY; ENZYME ACTIVITY; ENZYME REGULATION; EXCITABILITY; EXCITOTOXICITY; FOOD INTAKE; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MOLECULAR MECHANICS; NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; DIABETES MELLITUS, TYPE 2; EATING; ENERGY METABOLISM; HUMANS; INSULIN RESISTANCE; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 64249129005     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.10.014     Document Type: Review

References (352)

1. Kodl C.T., and Seaquist E.R. Cognitive dysfunction and diabetes mellitus 1. Endocr. Rev. 29 (2008) 494
2. Perlmuter L.C., Hakami M.K., Hodgson-Harrington C., Ginsberg J., Katz J., Singer D.E., and Nathan D.M. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am. J. Med. 77 (1984) 1043
3. Haan M.N. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat. Clin. Pract. Neurol. 2 (2006) 159
4. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., and Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53 (1999) 1937
5. Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L.A., Nilsson L., Persson G., Oden A., and Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet 347 (1996) 1141
6. Leibson C.L., O'Brien P.C., Atkinson E., Palumbo P.J., and Melton III L.J. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study. Am. J. Epidemiol. 146 (1997) 12
7. Stolk R.P., Pols H.A., Lamberts S.W., de Jong P.T., Hofman A., and Grobbee D.E. Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. Am. J. Epidemiol. 145 (1997) 24
8. Stolk R.P., Breteler M.M., Ott A., Pols H.A., Lamberts S.W., Grobbee D.E., and Hofman A. Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care 20 (1997) 792
9. Kilander L., Nyman H., Boberg M., Hansson L., and Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 31 (1998) 780
10. Grant W.B. Dietary links to Alzheimer's disease: 1999 update. J. Alzheimer's Dis. 1 (1999) 197
11. Myers A., Holmans P., Marshall H., Kwon J., Meyer D., Ramic D., Shears S., Booth J., DeVrieze F.W., Crook R., Hamshere M., Abraham R., Tunstall N., Rice F., Carty S., Lillystone S., Kehoe P., Rudrasingham V., Jones L., Lovestone S., Perez-Tur J., Williams J., Owen M.J., Hardy J., and Goate A.M. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290 (2000) 2304
12. Petot G.J., Traore F., Debanne S.M., Lerner A.J., Smyth K.A., and Friedland R.P. Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. Metabolism 52 (2003) 279
13. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., and Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53 (2004) 474
14. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J. Neural Transm. 105 (1998) 415
15. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp. Gerontol. 35 (2000) 1363
16. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J. Neural Transm. 109 (2002) 341
17. Watson G.S., and Craft S. Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. J. Neurol. Sci. 245 (2006) 21
18. Cole G.M., and Frautschy S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp. Gerontol. 42 (2007) 10
19. de la Monte S.M., Tong M., Lester-Coll N., Plater Jr. M., and Wands J.R. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimer's Dis. 10 (2006) 89
20. de la Monte S.M., and Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimer's Dis. 7 (2005) 45
21. Hoyer S. Brain glucose and energy metabolism during normal aging. Aging (Milano) 2 (1990) 245
22. Magistretti P.J. Neuron-glia metabolic coupling and plasticity. J. Exp. Biol. 209 (2006) 2304
23. Dunne M.J., Cosgrove K.E., Shepherd R.M., Aynsley-Green A., and Lindley K.J. Hyperinsulinism in infancy: from basic science to clinical disease. Physiol. Rev. 84 (2004) 239
24. Richardson J.T.E. Cognitive function in diabetes-mellitus. Neurosci. Biobehav. Rev. 14 (1990) 385
25. Tun P.A., Nathan D.M., and Perlmuter L.C. Cognitive and affective disorders in elderly diabetics. Clin. Geriatr. Med. 6 (1990) 731
26. Strachan M.W., Deary I.J., Ewing F.M., and Frier B.M. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20 (1997) 438
27. Helkala E.L., Niskanen L., Viinamaki H., Partanen J., and Uusitupa M. Short-term and long-term memory in elderly patients with NIDDM. Diabetes Care 18 (1995) 681
28. de Weid D., Bohus B., and Wimersma Greidanus T.B. Memory deficit in rats with hereditary diabetes insipidus. Brain Res. 85 (1975) 152
29. Biessels G.J., Kamal A., Ramakers G.M., Urban I.J., Spruijt B.M., Erkelens D.W., and Gispen W.H. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 45 (1996) 1259
30. McNay E.C., and Sherwin R.S. Effect of recurrent hypoglycemia on spatial cognition and cognitive metabolism in normal and diabetic rats. Diabetes 53 (2004) 418
31. McNay E.C., Williamson A., McCrimmon R.J., and Sherwin R.S. Cognitive and neural hippocampal effects of long-term moderate recurrent hypoglycemia. Diabetes 55 (2006) 1088
32. Dou J.T., Chen M., Dufour F., Alkon D.L., and Zhao W.Q. Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn. Mem. 12 (2005) 646
33. Moreira T., Malec E., Ostenson C.G., Efendic S., and Liljequist S. Diabetic type II Goto-Kakizaki rats show progressively decreasing exploratory activity and learning impairments in fixed and progressive ratios of a lever-press task. Behav. Brain Res. 180 (2007) 28
34. Li Z.G., Zhang W., and Sima A.A. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56 (2007) 1817
35. Stranahan A.M., and Mattson M.P. Impact of Energy Intake and Expenditure on Neuronal Plasticity. Neuromol. Med. (2008) Jun 10 [Electronic publication ahead of print].
36. Stranahan A.M., Arumugam T.V., Cutler R.G., Lee K., Egan J.M., and Mattson M.P. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11 (2008) 309
37. Minoshima S., Koeppe R.A., Frey K.A., Ishihara M., and Kuhl D.E. Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. J. Nucl. Med. 35 (1994) 949
38. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., and Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334 (1996) 752
39. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., and Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3334
40. Small G.W., La Rue A., Komo S., Kaplan A., and Mandelkern M.A. Predictors of cognitive change in middle-aged and older adults with memory loss. Am. J. Psychiatry 152 (1995) 1757
41. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Lavretsky H., Miller K., Siddarth P., Rasgon N.L., Mazziotta J.C., Saxena S., Wu H.M., Mega M.S., Cummings J.L., Saunders A.M., Pericak-Vance M.A., Roses A.D., Barrio J.R., and Phelps M.E. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6037
42. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., Imossi A., Thorn E., Bobinski M., Caraos C., Lesbre P., Schlyer D., Poirier J., Reisberg B., and Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/poitron-emission tomography (FDG/PET)40. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10966
43. Foster N.L., Chase T.N., Mansi L., Brooks R., Fedio P., Patronas N.J., and Di Chiro G. Cortical abnormalities in Alzheimer's disease. Ann. Neurol. 16 (1984) 649
44. Friedland R.P., Budinger T.F., Koss E., and Ober B.A. Alzheimer's disease: anterior-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci. Lett. 53 (1985) 235
45. Koss E., Friedland R.P., Ober B.A., and Jagust W.J. Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia. Am. J. Psychiatry 142 (1985) 638
46. Mosconi L., De Santi S., Li J., Tsui W.H., Li Y., Boppana M., Laska E., Rusinek H., and de Leon M.J. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging 29 (2008) 676
47. Mosconi L., Perani D., Sorbi S., Herholz K., Nacmias B., Holthoff V., Salmon E., Baron J.C., De Cristofaro M.T., Padovani A., Borroni B., Franceschi M., Bracco L., and Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63 (2004) 2332
48. Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., Reiman E.M., Holthoff V., Kalbe E., Sorbi S., Diehl-Schmid J., Perneczky R., Clerici F., Caselli R., Beuthien-Baumann B., Kurz A., Minoshima S., and de Leon M.J. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 49 (2008) 390
49. Reiman E.M., Chen K.W., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., and Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 284
50. Pettegrew J.W., Panchalingam K., Klunk W.E., McClure R.J., and Muenz L.R. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol. Aging 15 (1994) 117
51. Kennedy A.M., Frackowiak R.S., Newman S.K., Bloomfield P.M., Seaward J., Roques P., Lewington G., Cunningham V.J., and Rossor M.N. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186 (1995) 17
52. Valla J., Gonzalez-Lima F., and Reiman E.M. FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice. Int. J. Dev. Neurosci. 26 (2008) 253
53. Needham B.E., Wlodek M.E., Ciccotosto G.D., Fam B.C., Masters C.L., Proietto J., Andrikopoulos S., and Cappai R. Identification of the Alzheimer's disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. J. Pathol. 215 (2008) 155
54. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99
55. Ashe K.H. Synaptic structure and function in transgenic APP mice. Ann. N.Y. Acad. Sci. 924 (2000) 39
56. Bigl M., Apelt J., Eschrich K., and Schliebs R. Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology. J. Neural Transm. 110 (2003) 77
57. Pedersen W.A., and Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol. Dis. 17 (2004) 500
58. Choeiri C., Staines W., and Messier C. Immunohistochemical localization and quantification of glucose transporters in the mouse brain. Neuroscience 111 (2002) 19
59. Hooijmans C.R., Graven C., Dederen P.J., Tanila H., van Groen T., and Kiliaan A.J. Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res. 1181 (2007) 93
60. Bell G.I. Lilly lecture 1990. Molecular defects in diabetes mellitus. Diabetes 40 (1991) 413
61. Taylor S.I. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41 (1992) 1473
62. Le Roith D., and Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 24 (2001) 588
63. Heidenreich K.A., Zahniser N.R., Berhanu P., Brandenburg D., and Olefsky J.M. Structural differences between insulin receptors in the brain and peripheral target tissues. J. Biol. Chem. 258 (1983) 8527
64. Kuusisto J., Koivisto K., Mykkanen L., Helkala E.L., Vanhanen M., Hanninen T., Pyorala K., Riekkinen P., and Laakso M. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 22 (1993) 771
65. Kalmijn S., Feskens E.J., Launer L.J., Stijnen T., and Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 38 (1995) 1096
66. Frolich L., Blum-Degen D., Bernstein H.G., Engelsberger S., Humrich J., Laufer S., Muschner D., Thalheimer A., Turk A., Hoyer S., Zochling R., Boissl K.W., Jellinger K., and Riederer P. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural Transm. 105 (1998) 423
67. Frolich L., Blum-Degen D., Riederer P., and Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann. N.Y. Acad. Sci. 893 (1999) 290
68. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., and de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimer's Dis. 7 (2005) 63
69. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., and Porte Jr. D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50 (1998) 164
70. Craft S., Asthana S., Schellenberg G., Cherrier M., Baker L.D., Newcomer J., Plymate S., Latendresse S., Petrova A., Raskind M., Peskind E., Lofgreen C., and Grimwood K. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70 (1999) 146
71. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., and Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199 (2006) 265
72. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., and Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950
73. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., and Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18 (2004) 902
74. Wang J., Ho L., Qin W., Rocher A.B., Seror I., Humala N., Maniar K., Dolios G., Wang R., Hof P.R., and Pasinetti G.M. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 19 (2005) 659
75. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem Jr. N., Frautschy S.A., and Cole G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25 (2005) 3032
76. Haass C., Koo E.H., Mellon A., Hung A.Y., and Selkoe D.J. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357 (1992) 500
77. M. Shoji, T.E. Golde, J. Ghiso, T.T. Cheung, S. Estus, L.M. Shaffer, X.D. Cai, D.M. McKay, R. Tintner, B. Frangione, and ., Production of the Alzheimer amyloid beta protein by normal proteolytic processing, Science 258 (1992) 126.
78. Westermark P. Fine structure of islets of Langerhans in insular amyloidosis. Virchows Arch., A Pathol. Pathol. Anat. 359 (1973) 1
79. Westermark P., Wernstedt C., Wilander E., Hayden D.W., O'Brien T.D., and Johnson K.H. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3881
80. Cooper G.J., Willis A.C., Clark A., Turner R.C., Sim R.B., and Reid K.B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 8628
81. Woods S.C., Lutz T.A., Geary N., and Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos. Trans. R. Soc. Lond., B. Biol. Sci. 361 (2006) 1219
82. Arora S., and Anubhuti. Role of neuropeptides in appetite regulation and obesity - a review. Neuropeptides 40 (2006) 375
83. Betsholtz C., Christmansson L., Engstrom U., Rorsman F., Svensson V., Johnson K.H., and Westermark P. Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett. 251 (1989) 261
84. Westermark P., Engstrom U., Johnson K.H., Westermark G.T., and Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 5036
85. Hoppener J.W., Oosterwijk C., Nieuwenhuis M.G., Posthuma G., Thijssen J.H., Vroom T.M., Ahren B., and Lips C.J. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42 (1999) 427
86. Porat Y., Kolusheva S., Jelinek R., and Gazit E. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42 (2003) 10971
87. Green J.D., Goldsbury C., Kistler J., Cooper G.J., and Aebi U. Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. J. Biol. Chem. 279 (2004) 12206
88. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486
89. Mirzabekov T.A., Lin M.C., and Kagan B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271 (1996) 1988
90. Anguiano M., Nowak R.J., and Lansbury P.T. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41 (2002) 11338
91. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., and Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279 (2004) 46363
92. Meier J.J., Kayed R., Lin C.Y., Gurlo T., Haataja L., Jayasinghe S., Langen R., Glabe C.G., and Butler P.C. Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am. J. Physiol., Endocrinol. Metab. 291 (2006) E1317-E1324
93. Huang C.J., Lin C.Y., Haataja L., Gurlo T., Butler A.E., Rizza R.A., and Butler P.C. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56 (2007) 2016
94. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N.Y. Acad. Sci. 924 (2000) 17
95. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789
96. Kelly J.W. The environmental dependency of protein folding best explains prion and amyloid diseases. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 930
97. Dobson C.M. The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond., B. Biol. Sci. 356 (2001) 133
98. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46 (1995) 223
99. Nogueira-Machado J.A., and Chaves M.M. From hyperglycemia to AGE-RAGE interaction on the cell surface: a dangerous metabolic route for diabetic patients. Expert Opin. Ther. Targets 12 (2008) 871
100. Small S.A., and Gandy S. Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis. Neuron 52 (2006) 15
101. Smith M.A., Monnier V.M., Sayre L.M., and Perry G. Amyloidosis, advanced glycation end products and Alzheimer disease. NeuroReport 6 (1995) 1595
102. Smith M.A., Sayre L.M., Monnier V.M., and Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18 (1995) 172
103. Smith M.A., Sayre L.M., Vitek M.P., Monnier V.M., and Perry G. Early AGEing and Alzheimer's. Nature 374 (1995) 316
104. Hammes H.P., Ali S.S., Uhlmann M., Weiss A., Federlin K., Geisen K., and Brownlee M. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia 38 (1995) 269
105. Knecht K.J., Feather M.S., and Baynes J.W. Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo. Arch. Biochem. Biophys. 294 (1992) 130
106. Mitsuhashi T., Nakayama H., Itoh T., Kuwajima S., Aoki S., Atsumi T., and Koike T. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes 42 (1993) 826
107. Nakayama H., Mitsuhashi T., Kuwajima S., Aoki S., Kuroda Y., Itoh T., and Nakagawa S. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes 42 (1993) 345
108. Munch G., Schinzel R., Loske C., Wong A., Durany N., Li J.J., Vlassara H., Smith M.A., Perry G., and Riederer P. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J. Neural Transm. 105 (1998) 439
109. Schmidt A.M., Hori O., Cao R., Yan S.D., Brett J., Wautier J.L., Ogawa S., Kuwabara K., Matsumoto M., and Stern D. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45 Suppl. 3 (1996) S77-S80
110. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., Hong M., Luther T., Henle T., Kloting I., Morcos M., Hofmann M., Tritschler H., Weigle B., Kasper M., Smith M., Perry G., Schmidt A.M., Stern D.M., Haring H.U., Schleicher E., and Nawroth P.P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50 (2001) 2792
111. Deane R., Du Y.S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., and Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9 (2003) 907
112. Munch G., Thome J., Foley P., Schinzel R., and Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res. Brain Res. Rev. 23 (1997) 134
113. Reddy V.P., Obrenovich M.E., Atwood C.S., Perry G., and Smith M.A. Involvement of Maillard reactions in Alzheimer disease. Neurotox. Res. 4 (2002) 191
114. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., and Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4766
115. Chen F., David D., Ferrari A., and Gotz J. Posttranslational modifications of tau-role in human tauopathies and modeling in transgenic animals. Curr. Drug Targets 5 (2004) 503
116. Necula M., and Kuret J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem. 279 (2004) 49694
117. Smith M.A., Rudnicka-Nawrot M., Richey P.L., Praprotnik D., Mulvihill P., Miller C.A., Sayre L.M., and Perry G. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J. Neurochem. 64 (1995) 2660
118. Ko L.W., Ko E.C., Nacharaju P., Liu W.K., Chang E., Kenessey A., and Yen S.H. An immunochemical study on tau glycation in paired helical filaments. Brain Res. 830 (1999) 301
119. Li J.J., Surini M., Catsicas S., Kawashima E., and Bouras C. Age-dependent accumulation of advanced glycosylation end products in human neurons. Neurobiol. Aging 16 (1995) 69
120. Shuvaev V.V., Laffont I., Serot J.M., Fujii J., Taniguchi N., and Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 22 (2001) 397
121. Smith M.A., Siedlak S.L., Richey P.L., Nagaraj R.H., Elhammer A., and Perry G. Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res. 717 (1996) 99
122. Chaney M.O., Stine W.B., Kokjohn T.A., Kuo Y.M., Esh C., Rahman A., Luehrs D.C., Schmidt A.M., Stern D., Yan S.D., and Roher A.E. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim. Biophys. Acta 1741 (2005) 199
123. Du Y.S., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godman G.C., Stern D., and Schmidt A.M. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5296
124. Arancio O., Zhang H.P., Chen X., Lin C., Trinchese F., Puzzo D., Liu S., Hegde A., Yan S.F., Stern A., Luddy J.S., Lue L.F., Walker D.G., Roher A., Buttini M., Mucke L., Li W., Schmidt A.M., Kindy M., Hyslop P.A., Stern D.M., and Du Yan S.S. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 23 (2004) 4096
125. Lue L.F., Walker D.G., and Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol. Aging 22 (2001) 945
126. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., and Yan S.D. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171 (2001) 29
127. Moreira P.I., Smith M.A., Zhu X., Nunomura A., Castellani R.J., and Perry G. Oxidative stress and neurodegeneration. Ann. N.Y. Acad. Sci. 1043 (2005) 545
128. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., and Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685
129. Yan S.D., Stern D., Kane M.D., Kuo Y.M., Lampert H.C., and Roher A.E. RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease. Restor. Neurol. Neurosci. 12 (1998) 167
130. Origlia N., Righi M., Capsoni S., Cattaneo A., Fang F., Stern D.M., Chen J.X., Schmidt A.M., Arancio O., Yan S.D., and Domenici L. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J. Neurosci. 28 (2008) 3521
131. Havrankova J., Brownstein M., and Roth J. Insulin receptors are widely but unevenly distributed in central nervous-system of rat. Clin. Res. 26 (1978) A491
132. Havrankova J., and Roth J. Insulin receptors are widely distributed in central nervous-system of rat. Nature 272 (1978) 827
133. Marks J.L., Porte D., Stahl W.L., and Baskin D.G. Localization of insulin-receptor messenger-RNA in rat-brain by insitu hybridization. Endocrinology 127 (1990) 3234
134. Zhao W.Q., Chen H., Xu H., Moore E., Meiri N., Quon M.J., and Alkon D.L. Brain insulin receptors and spatial memory - correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem. 274 (1999) 34893
135. Werther G.A., Hogg A., Oldfield B.J., Mckinley M.J., Figdor R., Allen A.M., and Mendelsohn F.A.O. Localization and characterization of insulin-receptors in rat-brain and pituitary-gland using invitro autoradiography and computerized densitometry. Endocrinology 121 (1987) 1562
136. Shemer J., Adamo M., Raizada M.K., Heffez D., Zick Y., and Leroith D. Insulin and IGF-I stimulate phosphorylation of their respective receptors in intact neuronal and glial cells in primary culture. J. Mol. Neurosci. 1 (1989) 3
137. Young W.S. Periventricular hypothalamic cells in the rat-brain contain insulin messenger-RNA. Neuropeptides 8 (1986) 93
138. Clarke D.W., Mudd L., Boyd F.T., Fields M., and Raizada M.K. Insulin is released from rat-brain neuronal cells in culture. J. Neurochem. 47 (1986) 831
139. Wei L., Matsumoto H., and Rhoads D.E. Release of immunoreactive insulin from rat-brain synaptosomes under depolarizing conditions. J. Neurochem. 54 (1990) 1661
140. Devaskar S.U., Giddings S.J., Rajakumar P.A., Carnaghi L.R., Menon R.K., and Zahm D.S. Insulin gene-expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 269 (1994) 8445
141. Schechter R., Beju D., Gaffney T., Schaefer F., and Whetsell L. Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system. Brain Res. 736 (1996) 16
142. Wozniak M., Rydzewski B., Baker S.P., and Raizada M.K. The cellular and physiological actions of insulin in the central-nervous-system. Neurochem. Int. 22 (1993) 1
143. Heidenreich K.A., and Gilmore P.R. Structural and functional-characteristics of insulin-receptors in rat neuro-blastoma cells. J. Neurochem. 45 (1985) 1642
144. Raizada M.K., Shemer J., Judkins J.H., Clarke D.W., Masters B.A., and Leroith D. Insulin-receptors in the brain - structural and physiological characterization. Neurochem. Res. 13 (1988) 297
145. Seino S., and Bell G.I. Alternative splicing of human insulin-receptor messenger-RNA. Biochem. Biophys. Res. Commun. 159 (1989) 312
146. Goldstein B.J., and Dudley A.L. The rat insulin-receptor - primary structure and conservation of tissue-specific alternative messenger-RNA splicing. Mol. Endocrinol. 4 (1990) 235
147. Goldstein B.J., and Dudley A.L. Heterogeneity of messenger-RNA that encodes the rat insulin-receptor is limited to the domain of exon 11 - analysis by RNA heteroduplex mapping, amplification of CDNA, and invitro translation. Diabetes 41 (1992) 1293
148. Kenner K.A., Kusari J., and Heidenreich K.A. CDNA sequence-analysis of the human brain insulin-receptor. Biochem. Biophys. Res. Commun. 217 (1995) 304
149. Huang Z., Bodkin N.L., Ortmeyer H.K., Hansen B.C., and Shuldiner A.R. Hyperinsulinemia is associated with altered insulin-receptor messenger-RNA splicing in muscle of the spontaneously obese-diabetic rhesus-monkey. J. Clin. Invest. 94 (1994) 1289
150. Sbraccia P., DAdamo M., Leonetti F., Caiola S., Iozzo P., Giaccari A., Buongiorno A., and Tamburrano G. Chronic primary hyperinsulinaemia is associated with altered insulin receptor mRNA splicing in muscle of patients with insulinoma. Diabetologia 39 (1996) 220
151. Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., Kondo T., Alber J., Galldiks N., Kustermann E., Arndt S., Jacobs A.H., Krone W., Kahn C.R., and Bruning J.C. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3100
152. Zhao W.Q., Chen H., Quon M.J., and Alkon D.L. Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490 (2004) 71
153. van der Heide L.P., Ramakers G.M.J., and Smidt M.P. Insulin signaling in the central nervous system: Learning to survive. Prog. Neurobiol. 79 (2006) 205
154. Woods S.C., and Porte Jr. D. The central nervous system, pancreatic hormones, feeding, and obesity. Adv. Metab. Disord. 9 (1978) 283
155. Woods S.C., Dorsa D.M., Figlewicz D.P., Baskin D.G., Stein L.J., Sipols A.J., and Porte D. Importance of the brain insulin system to food-intake. Appetite 6 (1985) 216
156. Baskin D.G., Figlewicz D.P., Woods S.C., Porte D., and Dorsa D.M. Insulin in the brain. Ann. Rev. Physiol. 49 (1987) 335
157. Bruning J.C., Gautam D., Gillette J.A., Krone W., and Kahn R.C. Brain-specific disruption of the insulin receptor gene in mice results in obesity, hyperinsulinemia and dyslipidemia. Diabetes 49 (2000) A279
158. Woods S.C., Schwartz M.W., Baskin D.G., and Seeley R.J. Food intake and the regulation of body weight. Ann. Rev. Psychol. 51 (2000) 255
159. Schwartz M.W., Woods S.C., Porte Jr. D., Seeley R.J., and Baskin D.G. Central nervous system control of food intake. Nature 404 (2000) 661
160. Plum L., Schubert M., and Bruning J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab. 16 (2005) 59
161. Fehm H.L., Kern W., and Peters A. The selfish brain: competition for energy resources. Hypothal. Integr. Energy Metab. 153 (2006) 129
162. Gerozissis K. Brain insulin and feeding: a bi-directional communication. Eur. J. Pharmacol. 490 (2004) 59
163. Gerozissis K. Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur. J. Pharmacol. 585 (2008) 38
164. Rotte M., Baerecke C., Pottag G., Klose S., Kanneberg E., Heinze H.J., and Lehnert H. Insulin affects the neuronal response in the medial temporal lobe in humans. Neuroendocrinology 81 (2005) 49
165. Eichenbaum H. Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron 44 (2004) 109
166. Kern W., Born J., Schreiber H., and Fehm H.L. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 48 (1999) 557
167. Kern W., Fruehwald-Schultes B., Peters A., Dodt C., Born J., and Fehm H.L. Effects of insulin on neurophysiological and behavioural measures of cognitive function in healthy humans. Diabetes 48 (1999) A438
168. Kern W., Peters A., Fruehwald-Schultes B., Deininger E., Born J., and Fehm H.L. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 74 (2001) 270
169. Park C.R., Seeley R.J., Craft S., and Woods S.C. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav. 68 (2000) 509
170. Benedict C., Hallschmid M., Schultes B., Born J., and Kern W. Intranasal insulin to improve memory function in humans. Neuroendocrinology 86 (2007) 136
171. Stockhorst U., de Fries D., Steingrueber H.J., and Scherbaum W.A. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol. Behav. 83 (2004) 47
172. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C.S., DeGroodt W., Mehta P., and Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70 (2008) 440
173. Reger M.A., Watson G.S., Green P.S., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Cherrier M.M., Schellenberg G.D., Frey W.H., and Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimer's Dis. 13 (2008) 323
174. Tomioka M., Adachi T., Suzuki H., Kunitomo H., Schafer W.R., and Iino Y. The insulin/PI 3-kinase pathway regulates salt chemotaxis learning in Caenorhabditis elegans. Neuron 51 (2006) 613
175. Bliss T.V.P., and Collingridge G.L. A synaptic model of memory - long-term potentiation in the hippocampus. Nature 361 (1993) 31
176. Artola A., and Singer W. Long-term depression of excitatory synaptic transmission and its relationship to long-term potentiation. Trends Neurosci. 16 (1993) 480
177. Zhuo M., and Hawkins R.D. Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system. Rev. Neurosci. 6 (1995) 259
178. Biessels G.J., Kamal A., Urban I.J.A., Spruijt B.M., Erkelens D.W., and Gispen W.H. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 800 (1998) 125
179. Di Luca M., Ruts L., Gardoni F., Cattabeni F., Biessels G.J., and Gispen W.H. NMDA receptor subunits are modified transcriptionally and post-translationally in the brain of streptozotocin-diabetic rats. Diabetologia 42 (1999) 693
180. Townsend M., Mehta T., and Selkoe D.J. Soluble A beta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282 (2007) 33305
181. Lisman J., and Raghavachari S. A unified model of the presynaptic and postsynaptic changes during LTP at CA1 synapses. Sci. STKE. 2006 (2006) re11
182. Lisman J.E., Raghavachari S., and Tsien R.W. The sequence of events that underlie quantal transmission at central glutamatergic synapses. Nat. Rev. Neurosci. 8 (2007) 597
183. Malinow R., and Malenka R.C. AMPA receptor trafficking and synaptic plasticity. Annu. Rev. Neurosci. 25 (2002) 103
184. Bredt D.S., and Nicoll R.A. AMPA receptor trafficking at excitatory synapses. Neuron 40 (2003) 361
185. Man H.Y., Ju W., Ahmadian G., and Wang Y.T. Intracellular trafficking of AMPA receptors in synaptic plasticity. Cell. Mol. Life Sci. 57 (2000) 1526
186. Wang Y.T., and Linden D.J. Expression of cerebellar long-term depression requires postsynaptic clathrin-mediated endocytosis. Neuron 25 (2000) 635
187. Wang Y.T. Probing the role of AMPAR endocytosis and long-term depression in behavioural sensitization: relevance to treatment of brain disorders, including drug addiction. Br. J. Pharmacol. 153 (2008) S389-S395
188. Man H.Y., Lin J.W., Ju W.H., Ahmadian G., Liu L.D., Becker L.E., Sheng M., and Wang Y.T. Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron 25 (2000) 649
189. Lin J.W., Ju W., Foster K., Lee S.H., Ahmadian G., Wyszynski M., Wang Y.T., and Sheng M. Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization. Nat. Neurosci. 3 (2000) 1282
190. Beattie E.C., Carroll R.C., Yu X., Morishita W., Yasuda H., von Zastrow M., and Malenka R.C. Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat. Neurosci. 3 (2000) 1291
191. Zhou Q., Xiao M., and Nicoll R.A. Contribution of cytoskeleton to the internalization of AMPA receptors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1261
192. Dalton G.L., Wang Y.T., Floresco S.B., and Phillips A.G. Disruption of AMPA receptor endocytosis impairs the extinction, but not acquisition of learned fear. Neuropsychopharmacology 33 (2008) 2416
193. van der Heide L.P., Kamal A., Artola A., Gispen W.H., and Ramakers G.M.J. Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-D-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner. J. Neurochem. 94 (2005) 1158
194. Chiu S.L., Chen C.M., and Cline H.T. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58 (2008) 708
195. Wan Q., Xiong Z.G., Man Y.H., Ackerley C.A., Braunton J., Lu W.Y., Becker L.E., MacDonald J.F., and Wang Y.T. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature 388 (1997) 686
196. Ma X.H., Zhong P., Gu Z.L., Feng J., and Yan Z. Muscarinic potentiation of GABA(A) receptor currents is gated by insulin signaling in the prefrontal cortex. J. Neurosci. 23 (2003) 1159
197. Vetiska S.M., Ahmadian G., Ju W., Liu L., Wymann M.P., and Wang Y.T. GABA(A) receptor-associated phosphoinositide 3-kinase is required for insulin-induced recruitment of postsynaptic GABA(A) receptors. Neuropharmacology 52 (2007) 146
198. Caraiscos V.B., Bonin R.P., Newell J.G., Czerwinska E., MacDonald J.F., and Orser B.A. Insulin increases the potency of glycine at ionotropic glycine receptors. Mol. Pharmacol. 71 (2007) 1277
199. Lynch J.W. Molecular structure and function of the glycine receptor chloride channel. Physiol. Rev. 84 (2004) 1051
200. Seely B.L., Reichart D.R., Takata Y., Yip C., and Olefsky J.M. A functional assessment of insulin insulin-like growth-factor-i hybrid receptors. Endocrinology 136 (1995) 1635
201. Li Z.G., Zhang W., Grunberger G., and Sima A.A. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res. 946 (2002) 221
202. Kasuga M., Zick Y., Blith D.L., Karlsson F.A., Haring H.U., and Kahn C.R. Insulin stimulation of phosphorylation of the beta-subunit of the insulin-receptor - formation of both phosphoserine and phosphotyrosine. J. Biol. Chem. 257 (1982) 9891
203. Kahn C.R., and Folli F. Molecular determinants of insulin action. Horm. Res. 39 (1993) 93
204. Taniguchi C.M., Emanuelli B., and Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7 (2006) 85
205. Khan A.H., and Pessin J.E. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 45 (2002) 1475
206. Cross D.A.E., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen-synthase kinase-3 by insulin-mediated by protein-kinase-B. Nature 378 (1995) 785
207. Girard J., Perdereau D., Foufelle F., Pripbuus C., and Ferre P. Regulation of lipogenic enzyme gene-expression by nutrients and hormones. FASEB J. 8 (1994) 36
208. Byon J.C.H., Kusari A.B., and Kusari J. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol. Cell. Biochem. 182 (1998) 101
209. Kennedy B.P., and Ramachandran C. Protein tyrosine phosphatase-1B in diabetes. Biochem. Pharmacol. 60 (2000) 877
210. Czech M.P. The nature and regulation of the insulin-receptor - structure and function. Ann. Rev. Physiol. 47 (1985) 357
211. Zachayus J.L., Cherqui G., and Plas C. Protein-kinase-c and insulin-receptor beta-subunit serine phosphorylation in cultured fetal-rat hepatocytes. Mol. Cell. Endocrinol. 105 (1994) 11
212. Mothe I., and VanObberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J. Biol. Chem. 271 (1996) 11222
213. EldarFinkelman H., and Krebs E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9660
214. Strack V., Hennige A.M., Krutzfeldt J., Bossenmaier B., Klein H.H., Kellerer M., Lammers R., and Haring H.U. Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms beta 2 and theta. Diabetologia 43 (2000) 443
215. Shulman G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106 (2000) 171
216. Saltiel A.R., and Pessin J.E. Insulin signaling pathways in time and space. Trends Cell Biol. 12 (2002) 65
217. Morisco C., Condorelli G., Trimarco V., Bellis A., Marrone C., Condorelli G., Sadoshima J., and Trimarco B. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ. Res. 96 (2005) 180
218. Draznin B. Molecular mechanisms of insulin resistance: Serine phosphorylation of insulin receptor substrate-1 and increased expression of p85 alpha - The two sides of a coin. Diabetes 55 (2006) 2392
219. Youngren J.F. Regulation of insulin receptor function. Cell. Mol. Life Sci. 64 (2007) 873
220. Takayama S., White M.F., Lauris V., and Kahn C.R. Phorbol esters modulate insulin receptor phosphorylation and insulin action in cultured hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 7797
221. Roth R.A., Liu F., and Chin J.E. Biochemical-mechanisms of insulin-resistance. Horm. Res. 41 (1994) 51
222. Pillay T.S., Xiao S., and Olefsky J.M. Glucose-induced phosphorylation of the insulin receptor functional effects and characterization of phosphorylation sites. J. Clin. Invest. 97 (1996) 613
223. Tian R. Another role for the celebrity Akt and insulin resistance. Circ. Res. 96 (2005) 139
224. De Fea K., and Roth R.A. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J. Biol. Chem. 272 (1997) 31400
225. De Fea K., and Roth R.A. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine. Biochemistry 36 (1997) 12939
226. Standaert M.L., and Pollet R.J. Receptor-mediated translocation and degradation of insulin in muscle-tissue. Clin. Res. 31 (1983) A853
227. Carpentier J.L., Fehlmann M., VanObberghen E., Gorden P., and Orci L. Redistribution of I-125-insulin on the surface of rat hepatocytes as a function of dissociation time. Diabetes 34 (1985) 1002
228. Di Guglielmo G.M., Drake P.G., Baass P.C., Authier F., Posner B.I., and Bergeron J.J.M. Insulin receptor internalization and signalling. Mol. Cell. Biochem. 182 (1998) 59
229. Marshall S., Green A., and Olefsky J.M. Evidence for recycling of insulin receptors in isolated rat adipocytes. J. Biol. Chem. 256 (1981) 11464
230. Knutson V.P. Proteolytic processing of the insulin-receptor beta-subunit is associated with insulin-induced receptor down-regulation1. J. Biol. Chem. 266 (1991) 15656
231. Kandel E.R., and Schwartz J.H. Molecular-biology of learning - modulation of transmitter release. Science 218 (1982) 433
232. Bank B., DeWeer A., Kuzirian A.M., Rasmussen H., and Alkon D.L. Classical conditioning induces long-term translocation of protein kinase C in rabbit hippocampal CA1 cells. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 1988
233. Soderling T.R., Fukunaga K., Rich D.P., Fong Y.L., Smith K., and Colbran R.J. Regulation of brain Ca-2+/calmodulin-dependent protein kinase-Ii. Adv. Second Messenger Phosphoprot. Res. 24 (1990) 206
234. Soderling T.R. Calcium/calmodulin-dependent protein-kinase .2. Role in learning and memory. Mol. Cell. Biochem. 128 (1993) 93
235. Soderling T.R., Tan S.E., Mcglademcculloh E., Yamamoto H., and Fukunaga K. Excitatory interactions between glutamate receptors and protein-kinases. J. Neurobiol. 25 (1994) 304
236. Nogues X. Protein kinase C, learning and memory: a circular determinism between physiology and behaviour. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 21 (1997) 507
237. VanderZee E.A., and Douma B.R.K. Historical review of research on protein kinase C in learning and memory. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 21 (1997) 379
238. Elgersma Y., and Silva A.J. Molecular mechanisms of synaptic plasticity and memory. Curr. Opin. Neurobiol. 9 (1999) 209
239. Adams J.P., and Sweatt J.D. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Ann. Rev. Pharmacol. Toxicol. 42 (2002) 135
240. Jaworski J., Spangler S., Seeburg D.P., Hoogenraad C.C., and Sheng M. Control of dendritic arborization by the phosphoinositide-3′-kinase-Akt-mammalian target of rapamycin pathway. J. Neurosci. 25 (2005) 11300
241. Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L.D., Lu J., Lo E., Wu D.C., Saule E., Bouschet T., Matthews P., Isaac J.T.R., Bortolotto Z.A., Wang Y.T., and Collingridge G.L. UP inhibits LTD in the hippocampus via regulation of GSK3 beta. Neuron 53 (2007) 703
242. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., and Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 22 (2008) 246
243. Mattson M.P. Calcium and neurodegeneration. Aging Cell 6 (2007) 337
244. Mattson M.P. Mitochondrial regulation of neuronal plasticity. Neurochem. Res. 32 (2007) 707
245. Greenamyre J.T., and Young A.B. Excitatory amino-acids and Alzheimers-disease. Neurobiol. Aging 10 (1989) 593
246. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., and Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55 (2007) 697
247. Sweeney G., and Klip A. Regulation of the Na+/K+-ATPase by insulin: why and how?. Mol. Cell. Biochem. 182 (1998) 121
248. Selkoe D.J., and Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. 43 (2003) 545
249. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545
250. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest. 115 (2005) 1121
251. Goate A., Chartierharlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericakvance M., Roses A., Williamson R., Rossor M., Owen M., and Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimers-disease. Nature 349 (1991) 704
252. Levy E., Carman M.D., Fernandezmadrid I.J., Power M.D., Lieberburg I., Vanduinen S.G., Bots G.T.A.M., Luyendijk W., and Frangione B. Mutation of the Alzheimers-disease amyloid gene in hereditary cerebral-hemorrhage, Dutch type. Science 248 (1990) 1124
253. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., and Younkin S.G. Familial Alzheimer's disease-linked presenilin 1 variants elevate A beta 1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996) 1005
254. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Pereztur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin. Nature 383 (1996) 710
255. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., LevyLahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996) 864
256. Citron M., Westaway D., Xia W.M., Carlson G., Diehl T., Levesque G., JohnsonWood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., Hyslop P.S., and Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3 (1997) 67
257. Kinoshita A., Shah T., Tangredi M.M., Strickland D.K., and Hyman B.T. The intracellular domain of the low density lipoprotein receptor-related protein modulates transactivation mediated by amyloid precursor protein and Fe. J. Biol. Chem. 278 (2003) 41182
258. Small S.A., and Gandy S. Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis. Neuron 52 (2006) 15
259. Gouras G.K., Almeida C.G., and Takahashi R.H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 26 (2005) 1235
260. Klein W.L., Krafft G.A., and Finch C.E. Targeting small A beta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219
261. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N.Y. Acad. Sci. 924 (2000) 17
262. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192 (2008) 106
263. Hilbich C., Kisterswoike B., Reed J., Masters C.L., and Beyreuther K. Human and rodent sequence analogs of Alzheimers amyloid beta-A4 share similar properties and can be solubilized in buffers of Ph 7. Eur. J. Biochem. 201 (1991) 61
264. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., and Glabe C. Assembly and aggregation properties of synthetic Alzheimers A4/beta amyloid peptide analogs. J. Biol. Chem. 267 (1992) 546
265. Jarrett J.T., Berger E.P., and Lansbury P.T. The carboxy terminus of the beta-amyloid protein is critical for the seeding of amyloid formation - implications for the pathogenesis of Alzheimers-disease1. Biochemistry 32 (1993) 4693
266. Klein W.L., Krafft G.A., and Finch C.E. Targeting small A beta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219
267. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Tran. 30 (2002) 552
268. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., and Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000) 1571
269. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6448
270. Catalano S.M., Dodson E.C., Henze D.A., Joyce J.G., Krafft G.A., and Kinney G.G. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr. Top. Med. Chem. 6 (2006) 597
271. Gong Y.S., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., and Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss4. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10417
272. Georganopoulou D.G., Chang L., Nam J.M., Thaxton C.S., Mufson E.J., Klein W.L., and Mirkin C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease1. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2273
273. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., and Klein W.L. A beta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease1. J. Neurosci. 27 (2007) 796
274. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352
275. Cheng I.H., Scearce-Levie K., Legleiter J., Palop J.J., Gerstein H., Bien-Ly N., Puolivali J., Lesne S., Ashe K.H., Muchowski P.J., and Mucke L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282 (2007) 23818
276. Walsh D.M., Klyubin I., Shankar G.M., Townsend M., Fadeeva J.V., Betts V., Podlisny M.B., Cleary J.P., Ashe K.H., Rowan M.J., and Selkoe D.J. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 33 (2005) 1087
277. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., and Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain3. Biochemistry 39 (2000) 10831
278. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D.M., and Selkoe D.J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers3. Ann. Neurol. 60 (2006) 668
279. Townsend M., Shankar G.M., Mehta T., Walsh D.M., and Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers4. J. Physiol. London 572 (2006) 477
280. Klyubin I., Betts V., Welzel A.T., Blennow K., Zetterberg H., Wallin A., Lemere C.A., Cullen W.K., Peng Y., Wisniewski T., Selkoe D.J., Anwyl R., Walsh D.M., and Rowan M.J. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization1. J. Neurosci. 28 (2008) 4231
281. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., and Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008) 837
282. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y.S., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., and Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24 (2004) 10191
283. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., and Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27 (2007) 2866
284. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S., Lacor P.N., Khuon D., Gong Y.S., Bigio E.H., Shaw P., De Felice F.G., Krafft G.A., and Klein W.L. Monoclonal antibodies that target pathological assemblies of A beta. J. Neurochem. 100 (2007) 23
285. Shughrue P.J., Acton P.J., Breese R.S., Zhao W.Q., Chen-Dodson E., Hepler R.W., Wolfe A.L., Matthews M., Heidecker G.J., Joyce J.G., Villarreal S.A., and Kinney G.G. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol. Aging (2008) May 15 [Electronic publication ahead of print]
286. Yankner B.A., Lu T., and Loerch P. The aging brain. Annu. Rev. Pathol. 3 (2008) 41
287. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., and Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosc. 8 (2005) 1051
288. Lee C.C., Kuo Y.M., Huang C.C., and Hsu K.S. Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol. Aging (2007) Aug 9 [Electronic publication ahead of print]
289. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., and O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging (2008) May 12 [Electronic publication ahead of print]
290. Xie L., Helmerhorst E., Taddei K., Plewright B., van Bronswijk W., and Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 22 (2002) RC221
291. Qiu W.Q., and Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis1. Neurobiol. Aging 27 (2006) 190
292. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., and Malinow R. AMPAR removal underlies A beta-induced synaptic depression and dendritic spine loss. Neuron 52 (2006) 831
293. Hotamisligil G. Stressed out about obesity and insulin resistance - Author's comments15. Nat. Med. 12 (2006) 42
294. Hotamisligil G.S. The role of TNF alpha and TNF receptors in obesity and insulin resistance18. J. Intern. Med. 245 (1999) 621
295. Hirosumi J., Tuncman G., Chang L.F., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. A central role for JNK in obesity and insulin resistance1. Nature 420 (2002) 333
296. Aguirre V., Uchida T., Yenush L., Davis R., and White M.F. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 275 (2000) 9047
297. White M.F. IRS proteins and the common path to diabetes. Am. J. Physiol. Endocrinol. Metab. 283 (2002) E413-E422
298. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downes C.P., and Lamb R.E. The TSC1-2 tumor suppressor controls insulin-P13K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2004) 213
299. Itani S.I., Zhou Q., Pories W.J., MacDonald K.G., and Dohm G.L. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 49 (2000) 1353
300. Itani S.I., Pories W.J., MacDonald K.G., and Dohm G.L. Increased protein kinase C theta in skeletal muscle of diabetic patients. Metab. Clin. Exp. 50 (2001) 553
301. Shah O.J., Wang Z.Y., and Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14 (2004) 1650
302. Mattson M.P., Barger S.W., Furukawa K., Bruce A.J., Wyss-Coray T., Mark R.J., and Mucke L. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res. Brain Res. Rev. 23 (1997) 47
303. Ragolia L., and Begum N. Protein phosphatase-1 and insulin action. Mol. Cell. Biochem. 182 (1998) 49
304. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.Q., Raber J., Masliah E., and Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9572
305. Pearson A.G., Byrne U.T., MacGibbon G.A., Faull R.L., and Dragunow M. Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains. Neurosci. Lett. 398 (2006) 246
306. Thakur A., Wang X., Siedlak S.L., Perry G., Smith M.A., and Zhu X. c-Jun phosphorylation in Alzheimer disease. J. Neurosci. Res. 85 (2007) 1668
307. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., and Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70 (1998) 2212
308. Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K., and Perry G. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502 (2000) 139
309. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., and O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93 (2005) 105
310. Abbott J.J., Howlett D.R., Francis P.T., and Williams R.J. A beta(1-42) modulation of Akt phosphorylation via alpha 7 nAChR and NMDA receptors. Neurobiol. Aging 29 (2008) 992
311. Ito S., Sawada M., Haneda M., Ishida Y., and Isobe K. Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci. Res. 56 (2006) 294
312. Duarte A.I., Santos P., Oliveira C.R., Santos M.S., and Rego A.C. Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression. Biochim. Biophys. Acta 1783 (2008) 994
313. Kenchappa P., Yadav A., Singh G., Nandana S., and Banerjee K. Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. J. Neurosci. Res. 76 (2004) 466
314. Yu X.R., Jia G.R., Gao G.D., Wang S.H., Han Y., and Cao W. Neuroprotection of insulin against oxidative stress-induced apoptosis in cultured retinal neurons: involvement of phosphoinositide 3-kinase/Akt signal pathway. Acta Biochim. Biophys. Sin. (Shanghai) 38 (2006) 241
315. Marchetti L., Klein M., Schlett K., Pfizenmaier K., and Eisel U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem. 279 (2004) 32869
316. Banks W.A. The source of cerebral insulin5. Eur. J. Pharmacol. 490 (2004) 5
317. Zhu X., Smith M.A., Honda K., Aliev G., Moreira P.I., Nunomura A., Casadesus G., Harris P.L., Siedlak S.L., and Perry G. Vascular oxidative stress in Alzheimer disease. J. Neurol. Sci. 257 (2007) 240
318. Hoppener J.W.M., Verbeek J.S., Dekoning E.J.P., Oosterwijk C., Vanhulst K.L., Visservernooy H.J., Hofhuis F.M.A., Vangaalen S., Berends M.J.H., Hackeng W.H.L., Jansz H.S., Morris J.F., Clark A., Capel P.J.A., and Lips C.J.M. Chronic overproduction of islet amyloid polypeptide amylin in transgenic mice - iysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycemia or hyperinsulinemia. Diabetologia 36 (1993) 1258
319. de Koning E.J., Morris E.R., Hofhuis F.M., Posthuma G., Hoppener J.W., Morris J.F., Capel P.J., Clark A., and Verbeek J.S. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8467
320. Frame S., and Zheleva D. Targeting glycogen synthase kinase-3 in insulin signalling2. Expert Opin. Ther. Targets 10 (2006) 429
321. Phiel C.J., Wilson C.A., Lee V.M., and Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423 (2003) 435
322. Ryder J., Yuan S., and Ni B.H. Akt/GSK3 beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell. Sign. 16 (2004) 187
323. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J. Alzheimer's Dis. 9 (2006) 309
324. Tesco G., and Tanzi R.E. GSK3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin - effects of the D257/D385A and FAD-linked mutations1. Mol. Basis Dement. 920 (2000) 227
325. Grimes C.A., and Jope R.S. The multifaceted roles of glycogen synthase kinase 3 beta in cellular signaling. Prog. Neurobiol. 65 (2001) 391
326. Kaytor M.D., and Orr H.T. The GSK3 beta signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 12 (2002) 275
327. Mazanetz M.P., and Fischer P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6 (2007) 464
328. Muyllaert D., Kremer A., Jaworski T., Borghgraef P., Devijver H., Croes S., Dewachter I., and Van Leuven F. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?. Genes Brain Behav. 7 Suppl. 1 (2008) 57
329. Harris-White M.E., and Frautschy S.A. Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 469
330. Hughes S.R., Khorkova O., Goyal S., Knaeblein J., Heroux J., Riedel N.G., and Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3275
331. Moir R.D., and Tanzi R.E. LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP. Curr. Alzheimer's Res. 2 (2005) 269
332. Qiu W.Q., Borth W., Ye Z., Haass C., Teplow D.B., and Selkoe D.J. Degradation of amyloid beta-protein by a serine protease-alpha(2)-macroglobulin complex. J. Biol. Chem. 271 (1996) 8443
333. Fulcher I.S., Matsas R., Turner A.J., and Kenny A.J. Kidney neutral endopeptidase and the hydrolysis of enkephalin by synaptic membranes show similar sensitivity to inhibitors. Biochem. J. 203 (1982) 519
334. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273 (1998) 32730
335. Turner A.J., Isaac R.E., and Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23 (2001) 261
336. Misra U.K., Gawdi G., Gonzalez-Gronow M., and Pizzo S.V. Coordinate regulation of the alpha(2)-macroglobulin signaling receptor and the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor by insulin. J. Biol. Chem. 274 (1999) 25785
337. Zhao L.X., Teter B., Morihara T., Lim G.P., Ambegaokar S.S., Ubeda O.J., Frautschy S.A., and Cole G.M. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer's disease intervention. J. Neurosci. 24 (2004) 11120
338. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., and Xu H.X. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21 (2001) 2561
339. Biessels G.J., and Kappelle L.J. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochem. Soc. Trans. 33 (2005) 1041
340. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp. Gerontol. 38 (2003) 941
341. Gems D., and Partridge L. Insulin/IGF signalling and ageing: seeing the bigger picture. Curr. Opin. Genet. Dev. 11 (2001) 287
342. Wolkow C.A., Kimura K.D., Lee M.S., and Ruvkun G. Regulation of C-elegans life-span by insulinlike signaling in the nervous system1. Science 290 (2000) 147
343. Clancy D.J., Gems D., Harshman L.G., Oldham S., Stocker H., Hafen E., Leevers S.J., and Partridge L. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 292 (2001) 104
344. Tatar M., Kopelman A., Epstein D., Tu M.P., Yin C.M., and Garofalo R.S. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science 292 (2001) 107
345. Bluher M., Kahn B.B., and Kahn C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299 (2003) 572
346. Selman C., Lingard S., Choudhury A.I., Batterham R.L., Claret M., Clements M., Ramadani F., Okkenhaug K., Schuster E., Blanc E., Piper M.D., Al Qassab H., Speakman J.R., Carmignac D., Robinson I.C.A., Thornton J.M., Gems D., Partridge L., and Withers D.J. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 22 (2008) 807
347. Piper M.D.W., Selman C., McElwee J.J., and Partridge L. Separating cause from effect: how does insulin/IGF signalling control lifespan in worms, flies and mice?. J. Intern. Med. 263 (2008) 179
348. Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S., Siddle K., Pierce S.B., Roth R.A., and Rutter W.J. Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 704
349. Taylor S.I., Kadowaki T., Kadowaki H., Accili D., Cama A., and McKeon C. Mutations in insulin-receptor gene in insulin-resistant patients. Diabetes Care 13 (1990) 257
350. Cama A., de la Luz S.M., Ottini L., Kadowaki T., Gorden P., Imperato-McGinley J., and Taylor S.I. A mutation in the tyrosine kinase domain of the insulin receptor associated with insulin resistance in an obese woman. J. Clin. Endocrinol. Metab. 73 (1991) 894
351. Liolitsa D., Powell J., and Lovestone S. Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 73 (2002) 261
352. W.Q. Zhao, J.T. Dou, Q.Y. Liu and D.L. Alkon, Evidence for locally produced insulin in the adult rat brain as a neuroactive pepetide 32nd SNF Meeting (2002). Poster M-28, #375.12.